Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mosquito-Borne Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

NCT01434381
View directory record Official record
Conditions
Malaria
Interventions
Pfs25-EPA/Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults

NCT00746798
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Anaheim, California • Colorado Springs, Colorado • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

NCT04131595
View directory record Official record
Conditions
Equine Encephalitis
Interventions
MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Trial of the PfSPZ Vaccine

NCT01001650
View directory record Official record
Conditions
Plasmodium Falciparum
Interventions
Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Factors Involved in Resistance to Severe Malaria

NCT00368810
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Human Immune Responses to Yellow Fever Vaccination

NCT00694655
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA)
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jun 10, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
View directory record Official record
Conditions
Dengue
Interventions
AT-752, Placebo Comparator
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450
View directory record Official record
Conditions
Malaria, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions
RPQ, SPQ, Primaquine Phosphate, Placebo
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jun 10, 2026, 1:54 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT06607003
View directory record Official record
Conditions
Malaria
Interventions
P. vivax challenge agent derived from PvHMB-CCE001
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 1:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea

NCT04969913
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

NCT03992872
View directory record Official record
Conditions
Chikungunya
Interventions
Chikungunya
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Deterick, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

NCT03483961
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Lenexa, Kansas • Kansas City, Missouri • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

NCT02511054
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 1:54 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

NCT07088822
View directory record Official record
Conditions
Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions
V4020
Biological
Lead sponsor
Medigen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

NCT01782300
View directory record Official record
Conditions
Dengue
Interventions
TV003 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

NCT03342898
View directory record Official record
Conditions
Dengue
Interventions
YF-17D, TDV, Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

NCT06334393
View directory record Official record
Conditions
Zika, Zika Virus Infection
Interventions
VLA1601, CpG 1018®, 3M-052-AF
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

NCT02450838
View directory record Official record
Conditions
Dengue
Interventions
V180, Alhydrogel™, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

NCT04072302
View directory record Official record
Conditions
Malaria
Interventions
KAF156, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria

NCT00295581
View directory record Official record
Conditions
Plasmodium Falciparum, Plasmodium Vivax Malaria
Interventions
PpPfs25/ISA51 & ScPvs25/ISA51
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

NCT00869713
View directory record Official record
Conditions
Rift Valley Fever
Interventions
Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 10, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

NCT01488890
View directory record Official record
Conditions
Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
7
States / cities
Alabaster, Alabama • Sacramento, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 10, 2026, 1:54 AM EDT